<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02087904</url>
  </required_header>
  <id_info>
    <org_study_id>M13-741</org_study_id>
    <secondary_id>2013-003467-60</secondary_id>
    <nct_id>NCT02087904</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis</brief_title>
  <official_title>A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2a, multicenter, randomized, double-blind, parallel group, placebo-controlled study
      to evaluate the safety, tolerability, efficacy and pharmacokinetic/pharmacodynamic effect of
      ABT-981 in patients with symptomatic, radiographic, and inflammatory knee osteoarthritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 4, 2014</start_date>
  <completion_date type="Actual">December 13, 2016</completion_date>
  <primary_completion_date type="Actual">June 7, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Scores of the Index Knee at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) numerical rating scale (NRS). The pain sub-score has a range of 0 (no pain) to 50 (maximum pain). A negative change from baseline indicates improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Quantitative Synovitis of the Index Knee at Week 26</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Change in synovitis of the index knee was evaluated using quantitative magnetic resonance imaging (MRI) measurements. MRI quantitative synovitis of the index knee was defined by mean synovial membrane thickness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Effusion Volume of the Index Knee at Week 26</measure>
    <time_frame>Baseline, Week 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Whole-Organ Magnetic Resonance Imaging Score (WORMS) Semi-Quantitative Synovitis/Effusion Score of the Index Knee at Week 26</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Semi-quantitative synovitis/effusion volume WORMS scores were scored as normal (0), &lt; 33% of maximum estimated distention (1), 33% - 66% of maximum estimated distention (2), or &gt; 66% of maximum estimated distention (3).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) NRS. The WOMAC physical function subscale score was 0 (normal) to 170 (least physical function). A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 26</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) NRS. The WOMAC physical function subscale score was 0 (normal) to 170 (least physical function). A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) NRS. The WOMAC physical function subscale score was 0 (normal) to 170 (least physical function). A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WOMAC Pain Scores of the Index Knee at Week 26</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) numerical rating scale (NRS). The pain sub-score has a range of 0 (no pain) to 50 (maximum pain). A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WOMAC Pain Scores of the Index Knee at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) numerical rating scale (NRS). The pain sub-score has a range of 0 (no pain) to 50 (maximum pain). A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Global Total Bone Marrow Lesion (BML) Score of the Index Knee Magnetic Resonance Imaging (MRI) at Week 26</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>BMLs in 15 regions were measured with MRI, and graded as 0 (normal), 1 (mild; &lt; 25% of region), 2 (moderate; 25% - 50% of region), or 3 (severe; &gt; 50% of region). The global total BML score was the sum of the 15 component scores, and ranged from 0 (normal) to 45 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Global Total BML Score of the Index Knee MRI at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>BMLs in 15 regions were measured with MRI, and graded as 0 (normal), 1 (mild; &lt; 25% of region), 2 (moderate; 25% - 50% of region), or 3 (severe; &gt; 50% of region). The global total BML score was the sum of the 15 component scores, and ranged from 0 (normal) to 45 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Index Knee Intermittent and Constant Osteoarthritis Pain (ICOAP) Scores at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The ICOAP is a multidimensional osteoarthritis-specific measure designed to comprehensively evaluate the pain experience in patients with hip or knee osteoarthritis. The ICOAP includes 11 items (5 constant pain items; 6 intermittent pain items). Each item is rated on a 0 to 4 point scale with a 7-day recall period. The raw maximum intermittent pain score ranges from 0 to 24, transformed to a reported scale of 0 (no pain) to 100 (worst pain). The raw maximum constant pain score ranges from 0 to 20, transformed to a reported scale of 0 (no pain) to 100 (worst pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Index Knee ICOAP Scores at Week 26</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>The ICOAP is a multidimensional osteoarthritis-specific measure designed to comprehensively evaluate the pain experience in patients with hip or knee osteoarthritis. The ICOAP includes 11 items (5 constant pain items; 6 intermittent pain items). Each item is rated on a 0 to 4 point scale with a 7-day recall period. The raw maximum intermittent pain score ranges from 0 to 24, transformed to a reported scale of 0 (no pain) to 100 (worst pain). The raw maximum constant pain score ranges from 0 to 20, transformed to a reported scale of 0 (no pain) to 100 (worst pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Index Knee ICOAP Scores at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>The ICOAP is a multidimensional osteoarthritis-specific measure designed to comprehensively evaluate the pain experience in patients with hip or knee osteoarthritis. The ICOAP includes 11 items (5 constant pain items; 6 intermittent pain items). Each item is rated on a 0 to 4 point scale with a 7-day recall period. The raw maximum intermittent pain score ranges from 0 to 24, transformed to a reported scale of 0 (no pain) to 100 (worst pain). The raw maximum constant pain score ranges from 0 to 20, transformed to a reported scale of 0 (no pain) to 100 (worst pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Index Knee Pain Intensity at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The index knee pain intensity was assessed in 3 different ways using an 11 -point NRS (0 to 10 points representing 'no pain' to 'worst possible pain'). Subjects were asked to enter: 1) average pain intensity during the past week (7-day recall period); 2) the worst pain during activity over the past 24 hours; 3) pain intensity before and after a 40 meter walk (performance pain, before and after). The 40 meter fast paced walk test is a test of short distance walking activity, walking speed over short distances and changing direction during walking. Individuals taking the test should walk as quickly but as safely as possible, without running, along a walkway and then turn around, and repeat again for a total distance of 40 m (132 feet). The total time taken to walk the 40 meters is recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Index Knee Pain Intensity at Week 26</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>The index knee pain intensity was assessed in 3 different ways using an 11 -point NRS (0 to 10 points representing 'no pain' to 'worst possible pain'). Subjects were asked to enter: 1) average pain intensity during the past week (7-day recall period); 2) the worst pain during activity over the past 24 hours; 3) pain intensity before and after a 40 meter walk (performance pain, before and after). The 40 meter fast paced walk test is a test of short distance walking activity, walking speed over short distances and changing direction during walking. Individuals taking the test should walk as quickly but as safely as possible, without running, along a walkway and then turn around, and repeat again for a total distance of 40 m (132 feet). The total time taken to walk the 40 meters is recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Index Knee Pain Intensity at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>The index knee pain intensity was assessed in 3 different ways using an 11 -point NRS (0 to 10 points representing 'no pain' to 'worst possible pain'). Subjects were asked to enter: 1) average pain intensity during the past week (7-day recall period); 2) the worst pain during activity over the past 24 hours; 3) pain intensity before and after a 40 meter walk (performance pain, before and after). The 40 meter fast paced walk test is a test of short distance walking activity, walking speed over short distances and changing direction during walking. Individuals taking the test should walk as quickly but as safely as possible, without running, along a walkway and then turn around, and repeat again for a total distance of 40 m (132 feet). The total time taken to walk the 40 meters is recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Global Assessment (PGA) of Arthritis of the Index Knee at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The PGA is a single item for evaluating overall osteoarthritis disease activity. PGA is assessed using an 11-point NRS of 0 to 10 points (representing best to worst disease status, respectively), with a 7-day recall period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PGA of Arthritis of the Index Knee at Week 26</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>The PGA is a single item for evaluating overall osteoarthritis disease activity. PGA is assessed using an 11-point NRS of 0 to 10 points (representing best to worst disease status, respectively), with a 7-day recall period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PGA of Arthritis of the Index Knee at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>The PGA is a single item for evaluating overall osteoarthritis disease activity. PGA is assessed using an 11-point NRS of 0 to 10 points (representing best to worst disease status, respectively), with a 7-day recall period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cartilage Volume of the Index Knee at Week 26</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Cartilage volume of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cartilage Volume of the Index Knee at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Cartilage volume of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cartilage Thickness of the Index Knee at Week 26</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Cartilage thickness of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cartilage Thickness of the Index Knee at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Cartilage thickness of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Percentage of participants classified as OMERACT-OARSI responders at Week 16. A subject was considered an OMERACT-OARSI responder if any of the following 3 criteria were met: 1. WOMAC Pain (in 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 2. WOMAC Function (in normalized 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 3. At least 2 of the following 3 are met: WOMAC Pain improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; WOMAC Function improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; PGA improvement ≥ 20% and absolute change (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline. Response rate 95% confidence interval based on normal approximation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>Percentage of participants classified as OMERACT-OARSI responders at Week 26. A subject was considered an OMERACT-OARSI responder if any of the following 3 criteria were met: 1. WOMAC Pain (in 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 2. WOMAC Function (in normalized 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 3. At least 2 of the following 3 are met: WOMAC Pain improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; WOMAC Function improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; PGA improvement ≥ 20% and absolute change (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline. Response rate 95% confidence interval based on normal approximation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Percentage of participants classified as OMERACT-OARSI responders at Week 52. A subject was considered an OMERACT-OARSI responder if any of the following 3 criteria were met: 1. WOMAC Pain (in 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 2. WOMAC Function (in normalized 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 3. At least 2 of the following 3 are met: WOMAC Pain improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; WOMAC Function improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; PGA improvement ≥ 20% and absolute change (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline. Response rate 95% confidence interval based on normal approximation.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <condition>Medial Compartment Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>ABT-981 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg ABT-981 subcutaneous (SC) every 2 weeks (E2W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-981 medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg ABT-981 SC E2W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-981 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg ABT-981 SC E2W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ABT-981</intervention_name>
    <arm_group_label>ABT-981 high dose</arm_group_label>
    <arm_group_label>ABT-981 low dose</arm_group_label>
    <arm_group_label>ABT-981 medium dose</arm_group_label>
    <other_name>Lutikizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Radiographic knee osteoarthritis with Kellgren-Lawrence Grade 2 or 3

          2. Body Mass Index (BMI) 18-34 kg/m2

          3. One or more clinical signs and symptoms of active inflammation in the index knee

        Exclusion Criteria:

          1. History of allergic reaction to any constituents of the study drug, or to any
             Immunoglobulin G (IgG)-containing product

          2. History of anaphylactic reaction to any agent

          3. Significant trauma or surgery to the index knee

          4. Severe knee malalignment

          5. Any uncontrolled medical illness or an unstable treatment or therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Levesque, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>March 13, 2014</study_first_submitted>
  <study_first_submitted_qc>March 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2014</study_first_posted>
  <results_first_submitted>July 15, 2019</results_first_submitted>
  <results_first_submitted_qc>August 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2019</results_first_posted>
  <disposition_first_submitted>August 25, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>August 25, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 29, 2017</disposition_first_posted>
  <last_update_submitted>August 9, 2019</last_update_submitted>
  <last_update_submitted_qc>August 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Synovitis</keyword>
  <keyword>Knee</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study included a screening period (approximately 45 days prior to first study drug dose) and a washout period (5 half-lives of the longest acting analgesic used, or 48 hours, whichever was longer, in which all standard of care analgesic medications were discontinued prior to the first study drug dose).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Matching placebo SC E2W</description>
        </group>
        <group group_id="P2">
          <title>ABT-981 25 mg</title>
          <description>25 mg ABT-981 SC E2W</description>
        </group>
        <group group_id="P3">
          <title>ABT-981 100 mg</title>
          <description>100 mg ABT-981 SC E2W</description>
        </group>
        <group group_id="P4">
          <title>ABT-981 200 mg</title>
          <description>200 mg ABT-981 SC E2W</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="87"/>
                <participants group_id="P4" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="65"/>
                <participants group_id="P4" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did Not Receive Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Modified intent-to-treat population: all participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Matching placebo SC E2W</description>
        </group>
        <group group_id="B2">
          <title>ABT-981 25 mg</title>
          <description>25 mg ABT-981 SC E2W</description>
        </group>
        <group group_id="B3">
          <title>ABT-981 100 mg</title>
          <description>100 mg ABT-981 SC E2W</description>
        </group>
        <group group_id="B4">
          <title>ABT-981 200 mg</title>
          <description>200 mg ABT-981 SC E2W</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="85"/>
            <count group_id="B2" value="89"/>
            <count group_id="B3" value="85"/>
            <count group_id="B4" value="88"/>
            <count group_id="B5" value="347"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.53" spread="8.850"/>
                    <measurement group_id="B2" value="61.63" spread="7.546"/>
                    <measurement group_id="B3" value="60.21" spread="8.194"/>
                    <measurement group_id="B4" value="59.05" spread="10.273"/>
                    <measurement group_id="B5" value="60.11" spread="8.792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="225"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Scores of the Index Knee at Week 16</title>
        <description>The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) numerical rating scale (NRS). The pain sub-score has a range of 0 (no pain) to 50 (maximum pain). A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>Modified Intent to Treat population: all subjects who received at least 1 dose of study drug, Last observation carried forward (LOCF; missing responses were imputed by calculation based on the last non-missing post-baseline component values).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Scores of the Index Knee at Week 16</title>
          <description>The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) numerical rating scale (NRS). The pain sub-score has a range of 0 (no pain) to 50 (maximum pain). A negative change from baseline indicates improvement.</description>
          <population>Modified Intent to Treat population: all subjects who received at least 1 dose of study drug, Last observation carried forward (LOCF; missing responses were imputed by calculation based on the last non-missing post-baseline component values).</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.9" lower_limit="-10.96" upper_limit="-6.90"/>
                    <measurement group_id="O2" value="-9.2" lower_limit="-11.23" upper_limit="-7.23"/>
                    <measurement group_id="O3" value="-11.8" lower_limit="-13.84" upper_limit="-9.75"/>
                    <measurement group_id="O4" value="-10.1" lower_limit="-12.10" upper_limit="-8.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.834</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and Kellgren-Lawrence (K-L) grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.13</ci_lower_limit>
            <ci_upper_limit>2.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.73</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.415</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.00</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Quantitative Synovitis of the Index Knee at Week 26</title>
        <description>Change in synovitis of the index knee was evaluated using quantitative magnetic resonance imaging (MRI) measurements. MRI quantitative synovitis of the index knee was defined by mean synovial membrane thickness.</description>
        <time_frame>Baseline, Week 26</time_frame>
        <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quantitative Synovitis of the Index Knee at Week 26</title>
          <description>Change in synovitis of the index knee was evaluated using quantitative magnetic resonance imaging (MRI) measurements. MRI quantitative synovitis of the index knee was defined by mean synovial membrane thickness.</description>
          <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" lower_limit="-0.107" upper_limit="0.011"/>
                    <measurement group_id="O2" value="0.01" lower_limit="-0.045" upper_limit="0.068"/>
                    <measurement group_id="O3" value="-0.08" lower_limit="-0.134" upper_limit="-0.016"/>
                    <measurement group_id="O4" value="0.01" lower_limit="-0.047" upper_limit="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.145</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.021</ci_lower_limit>
            <ci_upper_limit>0.141</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.52</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.11</ci_lower_limit>
            <ci_upper_limit>0.056</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.159</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.023</ci_lower_limit>
            <ci_upper_limit>0.139</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Effusion Volume of the Index Knee at Week 26</title>
        <time_frame>Baseline, Week 26</time_frame>
        <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Effusion Volume of the Index Knee at Week 26</title>
          <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="-2.498" upper_limit="2.562"/>
                    <measurement group_id="O2" value="0.26" lower_limit="-2.113" upper_limit="2.624"/>
                    <measurement group_id="O3" value="-1.04" lower_limit="-3.421" upper_limit="1.347"/>
                    <measurement group_id="O4" value="-1.49" lower_limit="-3.868" upper_limit="0.898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.897</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.193</ci_lower_limit>
            <ci_upper_limit>3.642</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.542</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 dose group and Placebo at each post-baseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.515</ci_lower_limit>
            <ci_upper_limit>2.377</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.385</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 dose group and Placebo at each post-baseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.95</ci_lower_limit>
            <ci_upper_limit>1.916</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Whole-Organ Magnetic Resonance Imaging Score (WORMS) Semi-Quantitative Synovitis/Effusion Score of the Index Knee at Week 26</title>
        <description>Semi-quantitative synovitis/effusion volume WORMS scores were scored as normal (0), &lt; 33% of maximum estimated distention (1), 33% - 66% of maximum estimated distention (2), or &gt; 66% of maximum estimated distention (3).</description>
        <time_frame>Baseline, Week 26</time_frame>
        <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Whole-Organ Magnetic Resonance Imaging Score (WORMS) Semi-Quantitative Synovitis/Effusion Score of the Index Knee at Week 26</title>
          <description>Semi-quantitative synovitis/effusion volume WORMS scores were scored as normal (0), &lt; 33% of maximum estimated distention (1), 33% - 66% of maximum estimated distention (2), or &gt; 66% of maximum estimated distention (3).</description>
          <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="-0.057" upper_limit="0.193"/>
                    <measurement group_id="O2" value="-0.01" lower_limit="-0.130" upper_limit="0.113"/>
                    <measurement group_id="O3" value="-0.08" lower_limit="-0.205" upper_limit="0.043"/>
                    <measurement group_id="O4" value="-0.07" lower_limit="-0.196" upper_limit="0.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.384</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.249</ci_lower_limit>
            <ci_upper_limit>0.096</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.095</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.324</ci_lower_limit>
            <ci_upper_limit>0.026</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.106</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.314</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 16</title>
        <description>The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) NRS. The WOMAC physical function subscale score was 0 (normal) to 170 (least physical function). A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>Modified intent to Treat population: all participants who received at least 1 dose of study drug, LOCF (missing responses were imputed by calculation based on the last non-missing post-baseline component values).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 16</title>
          <description>The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) NRS. The WOMAC physical function subscale score was 0 (normal) to 170 (least physical function). A negative change from baseline indicates improvement.</description>
          <population>Modified intent to Treat population: all participants who received at least 1 dose of study drug, LOCF (missing responses were imputed by calculation based on the last non-missing post-baseline component values).</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.7" lower_limit="-35.30" upper_limit="-22.15"/>
                    <measurement group_id="O2" value="-29.8" lower_limit="-36.27" upper_limit="-23.32"/>
                    <measurement group_id="O3" value="-36.3" lower_limit="-42.90" upper_limit="-29.69"/>
                    <measurement group_id="O4" value="-32.1" lower_limit="-38.64" upper_limit="-25.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.818</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.22</ci_lower_limit>
            <ci_upper_limit>8.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.109</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-7.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.83</ci_lower_limit>
            <ci_upper_limit>1.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.465</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.58</ci_lower_limit>
            <ci_upper_limit>5.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 26</title>
        <description>The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) NRS. The WOMAC physical function subscale score was 0 (normal) to 170 (least physical function). A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 26</time_frame>
        <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, LOCF (missing responses were imputed by calculation based on the last non-missing post-baseline component values).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 26</title>
          <description>The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) NRS. The WOMAC physical function subscale score was 0 (normal) to 170 (least physical function). A negative change from baseline indicates improvement.</description>
          <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, LOCF (missing responses were imputed by calculation based on the last non-missing post-baseline component values).</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.7" lower_limit="-36.61" upper_limit="-22.75"/>
                    <measurement group_id="O2" value="-31.8" lower_limit="-38.62" upper_limit="-24.98"/>
                    <measurement group_id="O3" value="-38.9" lower_limit="-45.83" upper_limit="-31.92"/>
                    <measurement group_id="O4" value="-36.9" lower_limit="-43.71" upper_limit="-30.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.666</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.76</ci_lower_limit>
            <ci_upper_limit>7.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.065</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-9.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.95</ci_lower_limit>
            <ci_upper_limit>0.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.145</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-7.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.84</ci_lower_limit>
            <ci_upper_limit>2.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 52</title>
        <description>The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) NRS. The WOMAC physical function subscale score was 0 (normal) to 170 (least physical function). A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, LOCF (missing responses were imputed by calculation based on the last non-missing post-baseline component values).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 52</title>
          <description>The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) NRS. The WOMAC physical function subscale score was 0 (normal) to 170 (least physical function). A negative change from baseline indicates improvement.</description>
          <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, LOCF (missing responses were imputed by calculation based on the last non-missing post-baseline component values).</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.9" lower_limit="-40.66" upper_limit="-25.12"/>
                    <measurement group_id="O2" value="-36.1" lower_limit="-43.76" upper_limit="-28.46"/>
                    <measurement group_id="O3" value="-38.7" lower_limit="-46.52" upper_limit="-30.92"/>
                    <measurement group_id="O4" value="-39.7" lower_limit="-47.37" upper_limit="-32.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.558</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.03</ci_lower_limit>
            <ci_upper_limit>7.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.295</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-5.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.77</ci_lower_limit>
            <ci_upper_limit>5.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.218</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-6.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.63</ci_lower_limit>
            <ci_upper_limit>4.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WOMAC Pain Scores of the Index Knee at Week 26</title>
        <description>The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) numerical rating scale (NRS). The pain sub-score has a range of 0 (no pain) to 50 (maximum pain). A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 26</time_frame>
        <population>Modified intent to Treat population: all subjects who received at least 1 dose of study drug, LOCF (missing responses were imputed by calculation based on the last non-missing post-baseline component values).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WOMAC Pain Scores of the Index Knee at Week 26</title>
          <description>The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) numerical rating scale (NRS). The pain sub-score has a range of 0 (no pain) to 50 (maximum pain). A negative change from baseline indicates improvement.</description>
          <population>Modified intent to Treat population: all subjects who received at least 1 dose of study drug, LOCF (missing responses were imputed by calculation based on the last non-missing post-baseline component values).</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" lower_limit="-11.29" upper_limit="-7.07"/>
                    <measurement group_id="O2" value="-9.8" lower_limit="-11.90" upper_limit="-7.75"/>
                    <measurement group_id="O3" value="-11.9" lower_limit="-13.99" upper_limit="-9.76"/>
                    <measurement group_id="O4" value="-11.6" lower_limit="-13.65" upper_limit="-9.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.664</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.58</ci_lower_limit>
            <ci_upper_limit>2.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.075</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.67</ci_lower_limit>
            <ci_upper_limit>0.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.107</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.33</ci_lower_limit>
            <ci_upper_limit>0.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WOMAC Pain Scores of the Index Knee at Week 52</title>
        <description>The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) numerical rating scale (NRS). The pain sub-score has a range of 0 (no pain) to 50 (maximum pain). A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Modified intent to Treat population: all participants who received at least 1 dose of study drug, LOCF (missing responses were imputed by calculation based on the last non-missing post-baseline component values).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WOMAC Pain Scores of the Index Knee at Week 52</title>
          <description>The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) numerical rating scale (NRS). The pain sub-score has a range of 0 (no pain) to 50 (maximum pain). A negative change from baseline indicates improvement.</description>
          <population>Modified intent to Treat population: all participants who received at least 1 dose of study drug, LOCF (missing responses were imputed by calculation based on the last non-missing post-baseline component values).</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" lower_limit="-12.24" upper_limit="-7.68"/>
                    <measurement group_id="O2" value="-11.0" lower_limit="-13.29" upper_limit="-8.80"/>
                    <measurement group_id="O3" value="-12.1" lower_limit="-14.42" upper_limit="-9.84"/>
                    <measurement group_id="O4" value="-12.2" lower_limit="-14.49" upper_limit="-10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.26</ci_lower_limit>
            <ci_upper_limit>2.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.186</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.39</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.157</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.46</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Global Total Bone Marrow Lesion (BML) Score of the Index Knee Magnetic Resonance Imaging (MRI) at Week 26</title>
        <description>BMLs in 15 regions were measured with MRI, and graded as 0 (normal), 1 (mild; &lt; 25% of region), 2 (moderate; 25% - 50% of region), or 3 (severe; &gt; 50% of region). The global total BML score was the sum of the 15 component scores, and ranged from 0 (normal) to 45 (severe).</description>
        <time_frame>Baseline, Week 26</time_frame>
        <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Global Total Bone Marrow Lesion (BML) Score of the Index Knee Magnetic Resonance Imaging (MRI) at Week 26</title>
          <description>BMLs in 15 regions were measured with MRI, and graded as 0 (normal), 1 (mild; &lt; 25% of region), 2 (moderate; 25% - 50% of region), or 3 (severe; &gt; 50% of region). The global total BML score was the sum of the 15 component scores, and ranged from 0 (normal) to 45 (severe).</description>
          <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-0.24" upper_limit="0.43"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.01" upper_limit="0.65"/>
                    <measurement group_id="O3" value="-0.0" lower_limit="-0.37" upper_limit="0.29"/>
                    <measurement group_id="O4" value="0.1" lower_limit="-0.22" upper_limit="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.319</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.564</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.966</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Global Total BML Score of the Index Knee MRI at Week 52</title>
        <description>BMLs in 15 regions were measured with MRI, and graded as 0 (normal), 1 (mild; &lt; 25% of region), 2 (moderate; 25% - 50% of region), or 3 (severe; &gt; 50% of region). The global total BML score was the sum of the 15 component scores, and ranged from 0 (normal) to 45 (severe).</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Global Total BML Score of the Index Knee MRI at Week 52</title>
          <description>BMLs in 15 regions were measured with MRI, and graded as 0 (normal), 1 (mild; &lt; 25% of region), 2 (moderate; 25% - 50% of region), or 3 (severe; &gt; 50% of region). The global total BML score was the sum of the 15 component scores, and ranged from 0 (normal) to 45 (severe).</description>
          <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-0.34" upper_limit="0.48"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-0.16" upper_limit="0.60"/>
                    <measurement group_id="O3" value="0.1" lower_limit="-0.30" upper_limit="0.48"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-0.36" upper_limit="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.602</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.953</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.55</ci_lower_limit>
            <ci_upper_limit>0.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.83</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Index Knee Intermittent and Constant Osteoarthritis Pain (ICOAP) Scores at Week 16</title>
        <description>The ICOAP is a multidimensional osteoarthritis-specific measure designed to comprehensively evaluate the pain experience in patients with hip or knee osteoarthritis. The ICOAP includes 11 items (5 constant pain items; 6 intermittent pain items). Each item is rated on a 0 to 4 point scale with a 7-day recall period. The raw maximum intermittent pain score ranges from 0 to 24, transformed to a reported scale of 0 (no pain) to 100 (worst pain). The raw maximum constant pain score ranges from 0 to 20, transformed to a reported scale of 0 (no pain) to 100 (worst pain).</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>Modified Intent to Treat population: all subjects who received at least 1 dose of study drug, observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Index Knee Intermittent and Constant Osteoarthritis Pain (ICOAP) Scores at Week 16</title>
          <description>The ICOAP is a multidimensional osteoarthritis-specific measure designed to comprehensively evaluate the pain experience in patients with hip or knee osteoarthritis. The ICOAP includes 11 items (5 constant pain items; 6 intermittent pain items). Each item is rated on a 0 to 4 point scale with a 7-day recall period. The raw maximum intermittent pain score ranges from 0 to 24, transformed to a reported scale of 0 (no pain) to 100 (worst pain). The raw maximum constant pain score ranges from 0 to 20, transformed to a reported scale of 0 (no pain) to 100 (worst pain).</description>
          <population>Modified Intent to Treat population: all subjects who received at least 1 dose of study drug, observed cases.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intermittent Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.2" lower_limit="-24.32" upper_limit="-16.08"/>
                    <measurement group_id="O2" value="-19.5" lower_limit="-23.40" upper_limit="-15.58"/>
                    <measurement group_id="O3" value="-21.3" lower_limit="-25.40" upper_limit="-17.26"/>
                    <measurement group_id="O4" value="-18.8" lower_limit="-22.92" upper_limit="-14.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constant Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.6" lower_limit="-22.88" upper_limit="-14.33"/>
                    <measurement group_id="O2" value="-17.7" lower_limit="-21.73" upper_limit="-13.62"/>
                    <measurement group_id="O3" value="-24.2" lower_limit="-28.39" upper_limit="-19.94"/>
                    <measurement group_id="O4" value="-20.0" lower_limit="-24.24" upper_limit="-15.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Intermittent pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.804</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.91</ci_lower_limit>
            <ci_upper_limit>6.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Intermittent pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.699</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.9</ci_lower_limit>
            <ci_upper_limit>4.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Intermittent pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.636</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.37</ci_lower_limit>
            <ci_upper_limit>7.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Constant pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.756</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.91</ci_lower_limit>
            <ci_upper_limit>6.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Constant pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.068</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-5.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.55</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Constant pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.649</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.34</ci_lower_limit>
            <ci_upper_limit>4.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Index Knee ICOAP Scores at Week 26</title>
        <description>The ICOAP is a multidimensional osteoarthritis-specific measure designed to comprehensively evaluate the pain experience in patients with hip or knee osteoarthritis. The ICOAP includes 11 items (5 constant pain items; 6 intermittent pain items). Each item is rated on a 0 to 4 point scale with a 7-day recall period. The raw maximum intermittent pain score ranges from 0 to 24, transformed to a reported scale of 0 (no pain) to 100 (worst pain). The raw maximum constant pain score ranges from 0 to 20, transformed to a reported scale of 0 (no pain) to 100 (worst pain).</description>
        <time_frame>Baseline, Week 26</time_frame>
        <population>Modified Intent to Treat population: all subjects who received at least 1 dose of study drug, observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Index Knee ICOAP Scores at Week 26</title>
          <description>The ICOAP is a multidimensional osteoarthritis-specific measure designed to comprehensively evaluate the pain experience in patients with hip or knee osteoarthritis. The ICOAP includes 11 items (5 constant pain items; 6 intermittent pain items). Each item is rated on a 0 to 4 point scale with a 7-day recall period. The raw maximum intermittent pain score ranges from 0 to 24, transformed to a reported scale of 0 (no pain) to 100 (worst pain). The raw maximum constant pain score ranges from 0 to 20, transformed to a reported scale of 0 (no pain) to 100 (worst pain).</description>
          <population>Modified Intent to Treat population: all subjects who received at least 1 dose of study drug, observed cases.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intermittent Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.7" lower_limit="-23.21" upper_limit="-14.21"/>
                    <measurement group_id="O2" value="-19.7" lower_limit="-23.99" upper_limit="-15.42"/>
                    <measurement group_id="O3" value="-21.3" lower_limit="-25.66" upper_limit="-16.98"/>
                    <measurement group_id="O4" value="-21.7" lower_limit="-26.11" upper_limit="-17.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constant Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.6" lower_limit="-24.22" upper_limit="-14.96"/>
                    <measurement group_id="O2" value="-18.8" lower_limit="-23.26" upper_limit="-14.42"/>
                    <measurement group_id="O3" value="-21.6" lower_limit="-26.05" upper_limit="-17.08"/>
                    <measurement group_id="O4" value="-22.1" lower_limit="-26.61" upper_limit="-17.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Intermittent pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.75</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.14</ci_lower_limit>
            <ci_upper_limit>5.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Intermittent pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.409</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.82</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Intermittent pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.338</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.24</ci_lower_limit>
            <ci_upper_limit>3.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Constant pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.817</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.59</ci_lower_limit>
            <ci_upper_limit>7.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Constant pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.544</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.37</ci_lower_limit>
            <ci_upper_limit>4.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Constant pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.437</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.91</ci_lower_limit>
            <ci_upper_limit>3.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Index Knee ICOAP Scores at Week 52</title>
        <description>The ICOAP is a multidimensional osteoarthritis-specific measure designed to comprehensively evaluate the pain experience in patients with hip or knee osteoarthritis. The ICOAP includes 11 items (5 constant pain items; 6 intermittent pain items). Each item is rated on a 0 to 4 point scale with a 7-day recall period. The raw maximum intermittent pain score ranges from 0 to 24, transformed to a reported scale of 0 (no pain) to 100 (worst pain). The raw maximum constant pain score ranges from 0 to 20, transformed to a reported scale of 0 (no pain) to 100 (worst pain).</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Index Knee ICOAP Scores at Week 52</title>
          <description>The ICOAP is a multidimensional osteoarthritis-specific measure designed to comprehensively evaluate the pain experience in patients with hip or knee osteoarthritis. The ICOAP includes 11 items (5 constant pain items; 6 intermittent pain items). Each item is rated on a 0 to 4 point scale with a 7-day recall period. The raw maximum intermittent pain score ranges from 0 to 24, transformed to a reported scale of 0 (no pain) to 100 (worst pain). The raw maximum constant pain score ranges from 0 to 20, transformed to a reported scale of 0 (no pain) to 100 (worst pain).</description>
          <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intermittent Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.2" lower_limit="-28.51" upper_limit="-17.83"/>
                    <measurement group_id="O2" value="-25.4" lower_limit="-30.21" upper_limit="-20.51"/>
                    <measurement group_id="O3" value="-23.6" lower_limit="-28.53" upper_limit="-18.64"/>
                    <measurement group_id="O4" value="-27.2" lower_limit="-32.19" upper_limit="-22.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constant Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.6" lower_limit="-25.93" upper_limit="-15.21"/>
                    <measurement group_id="O2" value="-21.8" lower_limit="-26.70" upper_limit="-16.94"/>
                    <measurement group_id="O3" value="-25.2" lower_limit="-30.14" upper_limit="-20.17"/>
                    <measurement group_id="O4" value="-29.7" lower_limit="-34.78" upper_limit="-24.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Intermittent pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.545</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.31</ci_lower_limit>
            <ci_upper_limit>4.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Intermittent pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.909</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.65</ci_lower_limit>
            <ci_upper_limit>6.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Intermittent pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.278</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.23</ci_lower_limit>
            <ci_upper_limit>3.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Constant pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.732</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.42</ci_lower_limit>
            <ci_upper_limit>5.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Constant pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.216</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-4.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.86</ci_lower_limit>
            <ci_upper_limit>2.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Constant pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.014</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-9.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.42</ci_lower_limit>
            <ci_upper_limit>-1.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline In Index Knee Pain Intensity at Week 16</title>
        <description>The index knee pain intensity was assessed in 3 different ways using an 11 -point NRS (0 to 10 points representing 'no pain' to 'worst possible pain'). Subjects were asked to enter: 1) average pain intensity during the past week (7-day recall period); 2) the worst pain during activity over the past 24 hours; 3) pain intensity before and after a 40 meter walk (performance pain, before and after). The 40 meter fast paced walk test is a test of short distance walking activity, walking speed over short distances and changing direction during walking. Individuals taking the test should walk as quickly but as safely as possible, without running, along a walkway and then turn around, and repeat again for a total distance of 40 m (132 feet). The total time taken to walk the 40 meters is recorded.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline In Index Knee Pain Intensity at Week 16</title>
          <description>The index knee pain intensity was assessed in 3 different ways using an 11 -point NRS (0 to 10 points representing 'no pain' to 'worst possible pain'). Subjects were asked to enter: 1) average pain intensity during the past week (7-day recall period); 2) the worst pain during activity over the past 24 hours; 3) pain intensity before and after a 40 meter walk (performance pain, before and after). The 40 meter fast paced walk test is a test of short distance walking activity, walking speed over short distances and changing direction during walking. Individuals taking the test should walk as quickly but as safely as possible, without running, along a walkway and then turn around, and repeat again for a total distance of 40 m (132 feet). The total time taken to walk the 40 meters is recorded.</description>
          <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7-Day Recall Period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" lower_limit="-2.86" upper_limit="-1.97"/>
                    <measurement group_id="O2" value="-2.4" lower_limit="-2.79" upper_limit="-1.95"/>
                    <measurement group_id="O3" value="-2.7" lower_limit="-3.09" upper_limit="-2.22"/>
                    <measurement group_id="O4" value="-2.1" lower_limit="-2.55" upper_limit="-1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activity Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" lower_limit="-2.85" upper_limit="-1.82"/>
                    <measurement group_id="O2" value="-2.4" lower_limit="-2.85" upper_limit="-1.87"/>
                    <measurement group_id="O3" value="-2.7" lower_limit="-3.19" upper_limit="-2.17"/>
                    <measurement group_id="O4" value="-2.1" lower_limit="-2.59" upper_limit="-1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Performance Pain (Before)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" lower_limit="-2.82" upper_limit="-1.89"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-2.58" upper_limit="-1.70"/>
                    <measurement group_id="O3" value="-2.5" lower_limit="-2.97" upper_limit="-2.06"/>
                    <measurement group_id="O4" value="-2.1" lower_limit="-2.52" upper_limit="-1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Performance Pain (After)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" lower_limit="-3.07" upper_limit="-2.11"/>
                    <measurement group_id="O2" value="-2.4" lower_limit="-2.90" upper_limit="-2.00"/>
                    <measurement group_id="O3" value="-2.7" lower_limit="-3.16" upper_limit="-2.22"/>
                    <measurement group_id="O4" value="-2.3" lower_limit="-2.77" upper_limit="-1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7-day recall period</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.874</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>0.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>7-day recall period</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.451</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.86</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>7-day recall period</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.331</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Activity pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.932</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Activity pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.344</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.07</ci_lower_limit>
            <ci_upper_limit>0.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Activity pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.489</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Performance pain (before)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.498</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.42</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Performance pain (before)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.637</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Performance pain (before)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.367</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Performance pain (after)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.67</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.51</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Performance pain (after)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.776</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.76</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Performance pain (after)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.387</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline In Index Knee Pain Intensity at Week 26</title>
        <description>The index knee pain intensity was assessed in 3 different ways using an 11 -point NRS (0 to 10 points representing 'no pain' to 'worst possible pain'). Subjects were asked to enter: 1) average pain intensity during the past week (7-day recall period); 2) the worst pain during activity over the past 24 hours; 3) pain intensity before and after a 40 meter walk (performance pain, before and after). The 40 meter fast paced walk test is a test of short distance walking activity, walking speed over short distances and changing direction during walking. Individuals taking the test should walk as quickly but as safely as possible, without running, along a walkway and then turn around, and repeat again for a total distance of 40 m (132 feet). The total time taken to walk the 40 meters is recorded.</description>
        <time_frame>Baseline, Week 26</time_frame>
        <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline In Index Knee Pain Intensity at Week 26</title>
          <description>The index knee pain intensity was assessed in 3 different ways using an 11 -point NRS (0 to 10 points representing 'no pain' to 'worst possible pain'). Subjects were asked to enter: 1) average pain intensity during the past week (7-day recall period); 2) the worst pain during activity over the past 24 hours; 3) pain intensity before and after a 40 meter walk (performance pain, before and after). The 40 meter fast paced walk test is a test of short distance walking activity, walking speed over short distances and changing direction during walking. Individuals taking the test should walk as quickly but as safely as possible, without running, along a walkway and then turn around, and repeat again for a total distance of 40 m (132 feet). The total time taken to walk the 40 meters is recorded.</description>
          <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7-Day Recall Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" lower_limit="-2.76" upper_limit="-1.73"/>
                    <measurement group_id="O2" value="-2.4" lower_limit="-2.89" upper_limit="-1.91"/>
                    <measurement group_id="O3" value="-2.8" lower_limit="-3.29" upper_limit="-2.31"/>
                    <measurement group_id="O4" value="-2.5" lower_limit="-2.98" upper_limit="-1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activity Pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" lower_limit="-3.07" upper_limit="-1.91"/>
                    <measurement group_id="O2" value="-2.5" lower_limit="-3.10" upper_limit="-1.99"/>
                    <measurement group_id="O3" value="-2.8" lower_limit="-3.37" upper_limit="-2.25"/>
                    <measurement group_id="O4" value="-2.5" lower_limit="-3.10" upper_limit="-1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Performance Pain (Before)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" lower_limit="-2.72" upper_limit="-1.70"/>
                    <measurement group_id="O2" value="-2.2" lower_limit="-2.68" upper_limit="-1.71"/>
                    <measurement group_id="O3" value="-2.6" lower_limit="-3.13" upper_limit="-2.16"/>
                    <measurement group_id="O4" value="-2.7" lower_limit="-3.15" upper_limit="-2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Performance Pain (After)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" lower_limit="-3.01" upper_limit="-1.98"/>
                    <measurement group_id="O2" value="-2.4" lower_limit="-2.90" upper_limit="-1.92"/>
                    <measurement group_id="O3" value="-3.0" lower_limit="-3.53" upper_limit="-2.54"/>
                    <measurement group_id="O4" value="-2.6" lower_limit="-3.13" upper_limit="-2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7-day recall period</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.661</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.86</ci_lower_limit>
            <ci_upper_limit>0.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>7-day recall period</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.122</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.26</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>7-day recall period</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.507</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.94</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Activity pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.892</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.85</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Activity pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.433</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.12</ci_lower_limit>
            <ci_upper_limit>0.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Activity pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.92</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Performance pain (before)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.957</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.68</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Performance pain (before)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.222</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.13</ci_lower_limit>
            <ci_upper_limit>0.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Performance pain (before)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.209</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.15</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Performance pain (after)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.813</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Performance pain (after)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.135</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.25</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Performance pain (after)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.679</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.85</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline In Index Knee Pain Intensity at Week 52</title>
        <description>The index knee pain intensity was assessed in 3 different ways using an 11 -point NRS (0 to 10 points representing 'no pain' to 'worst possible pain'). Subjects were asked to enter: 1) average pain intensity during the past week (7-day recall period); 2) the worst pain during activity over the past 24 hours; 3) pain intensity before and after a 40 meter walk (performance pain, before and after). The 40 meter fast paced walk test is a test of short distance walking activity, walking speed over short distances and changing direction during walking. Individuals taking the test should walk as quickly but as safely as possible, without running, along a walkway and then turn around, and repeat again for a total distance of 40 m (132 feet). The total time taken to walk the 40 meters is recorded.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline In Index Knee Pain Intensity at Week 52</title>
          <description>The index knee pain intensity was assessed in 3 different ways using an 11 -point NRS (0 to 10 points representing 'no pain' to 'worst possible pain'). Subjects were asked to enter: 1) average pain intensity during the past week (7-day recall period); 2) the worst pain during activity over the past 24 hours; 3) pain intensity before and after a 40 meter walk (performance pain, before and after). The 40 meter fast paced walk test is a test of short distance walking activity, walking speed over short distances and changing direction during walking. Individuals taking the test should walk as quickly but as safely as possible, without running, along a walkway and then turn around, and repeat again for a total distance of 40 m (132 feet). The total time taken to walk the 40 meters is recorded.</description>
          <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7-Day Recall Period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" lower_limit="-3.51" upper_limit="-2.35"/>
                    <measurement group_id="O2" value="-2.9" lower_limit="-3.45" upper_limit="-2.39"/>
                    <measurement group_id="O3" value="-2.9" lower_limit="-3.43" upper_limit="-2.35"/>
                    <measurement group_id="O4" value="-3.1" lower_limit="-3.65" upper_limit="-2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activity Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" lower_limit="-3.48" upper_limit="-2.16"/>
                    <measurement group_id="O2" value="-3.0" lower_limit="-3.64" upper_limit="-2.43"/>
                    <measurement group_id="O3" value="-3.2" lower_limit="-3.77" upper_limit="-2.55"/>
                    <measurement group_id="O4" value="-3.0" lower_limit="-3.65" upper_limit="-2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Performance Pain (Before)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" lower_limit="-3.14" upper_limit="-2.03"/>
                    <measurement group_id="O2" value="-2.7" lower_limit="-3.24" upper_limit="-2.23"/>
                    <measurement group_id="O3" value="-3.0" lower_limit="-3.51" upper_limit="-2.49"/>
                    <measurement group_id="O4" value="-2.9" lower_limit="-3.46" upper_limit="-2.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Performance Pain (After)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" lower_limit="-3.47" upper_limit="-2.33"/>
                    <measurement group_id="O2" value="-3.0" lower_limit="-3.53" upper_limit="-2.50"/>
                    <measurement group_id="O3" value="-3.4" lower_limit="-3.90" upper_limit="-2.86"/>
                    <measurement group_id="O4" value="-3.2" lower_limit="-3.69" upper_limit="-2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7-day recall period</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.978</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.76</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>7-day recall period</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.925</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.75</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>7-day recall period</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.659</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.96</ci_lower_limit>
            <ci_upper_limit>0.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Activity pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.633</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Activity pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.46</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.23</ci_lower_limit>
            <ci_upper_limit>0.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Activity pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.663</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Performance pain (before)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.696</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.89</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Performance pain (before)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.278</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.16</ci_lower_limit>
            <ci_upper_limit>0.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Performance pain (before)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.357</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Performance pain (after)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.761</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.87</ci_lower_limit>
            <ci_upper_limit>0.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.218</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.02</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Performance pain (after)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.513</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.02</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Global Assessment (PGA) of Arthritis of the Index Knee at Week 16</title>
        <description>The PGA is a single item for evaluating overall osteoarthritis disease activity. PGA is assessed using an 11-point NRS of 0 to 10 points (representing best to worst disease status, respectively), with a 7-day recall period.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Global Assessment (PGA) of Arthritis of the Index Knee at Week 16</title>
          <description>The PGA is a single item for evaluating overall osteoarthritis disease activity. PGA is assessed using an 11-point NRS of 0 to 10 points (representing best to worst disease status, respectively), with a 7-day recall period.</description>
          <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" lower_limit="-2.94" upper_limit="-2.01"/>
                    <measurement group_id="O2" value="-2.4" lower_limit="-2.80" upper_limit="-1.92"/>
                    <measurement group_id="O3" value="-2.9" lower_limit="-3.34" upper_limit="-2.42"/>
                    <measurement group_id="O4" value="-2.6" lower_limit="-3.08" upper_limit="-2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.728</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.52</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.219</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.06</ci_lower_limit>
            <ci_upper_limit>0.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.673</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.79</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PGA of Arthritis of the Index Knee at Week 26</title>
        <description>The PGA is a single item for evaluating overall osteoarthritis disease activity. PGA is assessed using an 11-point NRS of 0 to 10 points (representing best to worst disease status, respectively), with a 7-day recall period.</description>
        <time_frame>Baseline, Week 26</time_frame>
        <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PGA of Arthritis of the Index Knee at Week 26</title>
          <description>The PGA is a single item for evaluating overall osteoarthritis disease activity. PGA is assessed using an 11-point NRS of 0 to 10 points (representing best to worst disease status, respectively), with a 7-day recall period.</description>
          <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" lower_limit="-2.96" upper_limit="-1.91"/>
                    <measurement group_id="O2" value="-2.4" lower_limit="-2.94" upper_limit="-1.94"/>
                    <measurement group_id="O3" value="-3.0" lower_limit="-3.48" upper_limit="-2.47"/>
                    <measurement group_id="O4" value="-2.7" lower_limit="-3.18" upper_limit="-2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.984</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.145</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.26</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.527</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.96</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PGA of Arthritis of the Index Knee at Week 52</title>
        <description>The PGA is a single item for evaluating overall osteoarthritis disease activity. PGA is assessed using an 11-point NRS of 0 to 10 points (representing best to worst disease status, respectively), with a 7-day recall period.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PGA of Arthritis of the Index Knee at Week 52</title>
          <description>The PGA is a single item for evaluating overall osteoarthritis disease activity. PGA is assessed using an 11-point NRS of 0 to 10 points (representing best to worst disease status, respectively), with a 7-day recall period.</description>
          <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" lower_limit="-3.62" upper_limit="-2.44"/>
                    <measurement group_id="O2" value="-2.9" lower_limit="-3.48" upper_limit="-2.41"/>
                    <measurement group_id="O3" value="-3.2" lower_limit="-3.71" upper_limit="-2.62"/>
                    <measurement group_id="O4" value="-3.5" lower_limit="-4.01" upper_limit="-2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.836</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.738</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.94</ci_lower_limit>
            <ci_upper_limit>0.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.22</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cartilage Volume of the Index Knee at Week 26</title>
        <description>Cartilage volume of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.</description>
        <time_frame>Baseline, Week 26</time_frame>
        <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cartilage Volume of the Index Knee at Week 26</title>
          <description>Cartilage volume of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.</description>
          <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
          <units>mm^3</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Global Knee</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-326.0" lower_limit="-400.83" upper_limit="-251.13"/>
                    <measurement group_id="O2" value="-325.5" lower_limit="-397.10" upper_limit="-253.83"/>
                    <measurement group_id="O3" value="-322.4" lower_limit="-400.20" upper_limit="-244.61"/>
                    <measurement group_id="O4" value="-359.0" lower_limit="-429.72" upper_limit="-288.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medial Central Condyle + Plateau</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-59.1" lower_limit="-83.12" upper_limit="-35.10"/>
                    <measurement group_id="O2" value="-54.9" lower_limit="-77.83" upper_limit="-31.90"/>
                    <measurement group_id="O3" value="-50.1" lower_limit="-75.13" upper_limit="-25.07"/>
                    <measurement group_id="O4" value="-57.5" lower_limit="-80.12" upper_limit="-34.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medial Condyle + Plateau</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-128.6" lower_limit="-166.76" upper_limit="-90.50"/>
                    <measurement group_id="O2" value="-126.5" lower_limit="-163.03" upper_limit="-90.02"/>
                    <measurement group_id="O3" value="-124.5" lower_limit="-164.13" upper_limit="-84.86"/>
                    <measurement group_id="O4" value="-114.9" lower_limit="-150.86" upper_limit="-78.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Global knee</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.992</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-101.59</ci_lower_limit>
            <ci_upper_limit>102.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Global knee</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.948</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-103.95</ci_lower_limit>
            <ci_upper_limit>111.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Global knee</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.523</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-33.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-134.76</ci_lower_limit>
            <ci_upper_limit>68.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Medial central condyle + plateau</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.799</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.47</ci_lower_limit>
            <ci_upper_limit>36.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Medial central condyle + plateau</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.609</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>9.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.62</ci_lower_limit>
            <ci_upper_limit>43.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Medial central condyle + plateau</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.923</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.97</ci_lower_limit>
            <ci_upper_limit>34.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Medial condyle + plateau</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.937</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.88</ci_lower_limit>
            <ci_upper_limit>54.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Medial condyle + plateau</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.882</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50.68</ci_lower_limit>
            <ci_upper_limit>58.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Medial condyle + plateau</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.602</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>13.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.05</ci_lower_limit>
            <ci_upper_limit>65.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cartilage Volume of the Index Knee at Week 52</title>
        <description>Cartilage volume of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cartilage Volume of the Index Knee at Week 52</title>
          <description>Cartilage volume of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.</description>
          <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
          <units>mm^3</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Global Knee</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-557.0" lower_limit="-659.86" upper_limit="-454.10"/>
                    <measurement group_id="O2" value="-598.7" lower_limit="-694.66" upper_limit="-502.76"/>
                    <measurement group_id="O3" value="-554.3" lower_limit="-654.92" upper_limit="-453.60"/>
                    <measurement group_id="O4" value="-583.1" lower_limit="-678.88" upper_limit="-487.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medial Central Condyle + Plateau</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-101.2" lower_limit="-134.56" upper_limit="-67.79"/>
                    <measurement group_id="O2" value="-126.3" lower_limit="-157.5" upper_limit="-95.09"/>
                    <measurement group_id="O3" value="-90.1" lower_limit="-122.89" upper_limit="-57.29"/>
                    <measurement group_id="O4" value="-113.0" lower_limit="-144.08" upper_limit="-81.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medial Condyle + Plateau</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-214.7" lower_limit="-273.77" upper_limit="-155.64"/>
                    <measurement group_id="O2" value="-255.0" lower_limit="-310.03" upper_limit="-199.97"/>
                    <measurement group_id="O3" value="-190.3" lower_limit="-248.05" upper_limit="-132.51"/>
                    <measurement group_id="O4" value="-242.8" lower_limit="-297.71" upper_limit="-187.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Global knee</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.554</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-41.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-180.49</ci_lower_limit>
            <ci_upper_limit>97.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Global knee</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.97</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-140.86</ci_lower_limit>
            <ci_upper_limit>146.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Global knee</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.713</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-26.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-165.47</ci_lower_limit>
            <ci_upper_limit>113.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Medial central condyle + plateau</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.272</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-25.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-70.12</ci_lower_limit>
            <ci_upper_limit>19.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Medial central condyle + plateau</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.64</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>11.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.63</ci_lower_limit>
            <ci_upper_limit>57.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Medial central condyle + plateau</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.608</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-11.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-56.94</ci_lower_limit>
            <ci_upper_limit>33.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Medial condyle + plateau</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.319</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-40.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-119.88</ci_lower_limit>
            <ci_upper_limit>39.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Medial condyle + plateau</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.56</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>24.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.05</ci_lower_limit>
            <ci_upper_limit>106.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Medial condyle + plateau</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.489</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-28.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-107.97</ci_lower_limit>
            <ci_upper_limit>51.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cartilage Thickness of the Index Knee at Week 26</title>
        <description>Cartilage thickness of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.</description>
        <time_frame>Baseline, Week 26</time_frame>
        <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cartilage Thickness of the Index Knee at Week 26</title>
          <description>Cartilage thickness of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.</description>
          <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Global Knee</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.047" lower_limit="-0.058" upper_limit="-0.036"/>
                    <measurement group_id="O2" value="-0.047" lower_limit="-0.058" upper_limit="-0.037"/>
                    <measurement group_id="O3" value="-0.048" lower_limit="-0.059" upper_limit="-0.037"/>
                    <measurement group_id="O4" value="-0.052" lower_limit="-0.062" upper_limit="-0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medial Central Condyle + Plateau</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.085" lower_limit="-0.122" upper_limit="-0.048"/>
                    <measurement group_id="O2" value="-0.077" lower_limit="-0.113" upper_limit="-0.042"/>
                    <measurement group_id="O3" value="-0.074" lower_limit="-0.113" upper_limit="-0.036"/>
                    <measurement group_id="O4" value="-0.076" lower_limit="-0.111" upper_limit="-0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medial Condyle + Plateau</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.046" lower_limit="-0.060" upper_limit="-0.031"/>
                    <measurement group_id="O2" value="-0.045" lower_limit="-0.059" upper_limit="-0.031"/>
                    <measurement group_id="O3" value="-0.047" lower_limit="-0.062" upper_limit="-0.032"/>
                    <measurement group_id="O4" value="-0.044" lower_limit="-0.058" upper_limit="-0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Global knee</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.972</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.015</ci_lower_limit>
            <ci_upper_limit>0.015</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Global knee</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.929</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.001</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.017</ci_lower_limit>
            <ci_upper_limit>0.015</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Global knee</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.543</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.005</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Medial central condyle + plateau</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.752</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.008</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.043</ci_lower_limit>
            <ci_upper_limit>0.059</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Medial central condyle + plateau</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.691</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.011</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.042</ci_lower_limit>
            <ci_upper_limit>0.064</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Medial central condyle + plateau</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.71</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.041</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Medial condyle + plateau</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.965</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.019</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Medial condyle + plateau</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.885</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.002</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.022</ci_lower_limit>
            <ci_upper_limit>0.019</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Medial condyle + plateau</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.887</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.001</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.018</ci_lower_limit>
            <ci_upper_limit>0.021</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cartilage Thickness of the Index Knee at Week 52</title>
        <description>Cartilage thickness of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cartilage Thickness of the Index Knee at Week 52</title>
          <description>Cartilage thickness of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.</description>
          <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, observed cases.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Global Knee</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.081" lower_limit="-0.095" upper_limit="-0.066"/>
                    <measurement group_id="O2" value="-0.085" lower_limit="-0.099" upper_limit="-0.072"/>
                    <measurement group_id="O3" value="-0.081" lower_limit="-0.095" upper_limit="-0.067"/>
                    <measurement group_id="O4" value="-0.083" lower_limit="-0.097" upper_limit="-0.070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medial Central Condyle + Plateau</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.136" lower_limit="-0.187" upper_limit="-0.084"/>
                    <measurement group_id="O2" value="-0.176" lower_limit="-0.224" upper_limit="-0.127"/>
                    <measurement group_id="O3" value="-0.113" lower_limit="-0.163" upper_limit="-0.062"/>
                    <measurement group_id="O4" value="-0.141" lower_limit="-0.190" upper_limit="-0.093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medial Condyle + Plateau</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.084" lower_limit="-0.106" upper_limit="-0.063"/>
                    <measurement group_id="O2" value="-0.096" lower_limit="-0.117" upper_limit="-0.076"/>
                    <measurement group_id="O3" value="-0.073" lower_limit="-0.094" upper_limit="-0.052"/>
                    <measurement group_id="O4" value="-0.087" lower_limit="-0.107" upper_limit="-0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Global knee</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.619</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.005</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.024</ci_lower_limit>
            <ci_upper_limit>0.014</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Global knee</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.952</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.001</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.019</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Global knee</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.765</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.003</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.022</ci_lower_limit>
            <ci_upper_limit>0.016</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Medial central condyle + plateau</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.258</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.11</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Medial central condyle + plateau</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.535</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.023</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.049</ci_lower_limit>
            <ci_upper_limit>0.094</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Medial central condyle + plateau</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.866</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.006</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.076</ci_lower_limit>
            <ci_upper_limit>0.064</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Medial condyle + plateau</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.413</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.012</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.041</ci_lower_limit>
            <ci_upper_limit>0.017</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Medial condyle + plateau</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.445</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.012</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.018</ci_lower_limit>
            <ci_upper_limit>0.042</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Medial condyle + plateau</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.835</p_value>
            <p_value_desc>P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.003</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.032</ci_lower_limit>
            <ci_upper_limit>0.026</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 16</title>
        <description>Percentage of participants classified as OMERACT-OARSI responders at Week 16. A subject was considered an OMERACT-OARSI responder if any of the following 3 criteria were met: 1. WOMAC Pain (in 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 2. WOMAC Function (in normalized 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 3. At least 2 of the following 3 are met: WOMAC Pain improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; WOMAC Function improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; PGA improvement ≥ 20% and absolute change (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline. Response rate 95% confidence interval based on normal approximation.</description>
        <time_frame>Week 16</time_frame>
        <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 16</title>
          <description>Percentage of participants classified as OMERACT-OARSI responders at Week 16. A subject was considered an OMERACT-OARSI responder if any of the following 3 criteria were met: 1. WOMAC Pain (in 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 2. WOMAC Function (in normalized 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 3. At least 2 of the following 3 are met: WOMAC Pain improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; WOMAC Function improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; PGA improvement ≥ 20% and absolute change (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline. Response rate 95% confidence interval based on normal approximation.</description>
          <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, LOCF.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="49.6" upper_limit="70.4"/>
                    <measurement group_id="O2" value="67.0" lower_limit="57.2" upper_limit="76.9"/>
                    <measurement group_id="O3" value="72.6" lower_limit="63.1" upper_limit="82.2"/>
                    <measurement group_id="O4" value="65.5" lower_limit="55.5" upper_limit="75.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.311</p_value>
            <p_value_desc>P-value for test of difference between each ABT-981 dose group and Placebo was from a Cochran-Mantel-Haenszel test using age group and K-L grade as stratification factors.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Response Rate Difference</param_type>
            <param_value>7.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>21.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.435</p_value>
            <p_value_desc>P-value for test of difference between each ABT-981 dose group and Placebo was from a Cochran-Mantel-Haenszel test using age group and K-L grade as stratification factors.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Response Rate Difference</param_type>
            <param_value>5.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.9</ci_lower_limit>
            <ci_upper_limit>19.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.435</p_value>
            <p_value_desc>P-value for test of difference between each ABT-981 dose group and Placebo was from a Cochran-Mantel-Haenszel test using age group and K-L grade as stratification factors.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Response Rate Difference</param_type>
            <param_value>5.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.9</ci_lower_limit>
            <ci_upper_limit>19.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 26</title>
        <description>Percentage of participants classified as OMERACT-OARSI responders at Week 26. A subject was considered an OMERACT-OARSI responder if any of the following 3 criteria were met: 1. WOMAC Pain (in 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 2. WOMAC Function (in normalized 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 3. At least 2 of the following 3 are met: WOMAC Pain improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; WOMAC Function improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; PGA improvement ≥ 20% and absolute change (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline. Response rate 95% confidence interval based on normal approximation.</description>
        <time_frame>Week 26</time_frame>
        <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 26</title>
          <description>Percentage of participants classified as OMERACT-OARSI responders at Week 26. A subject was considered an OMERACT-OARSI responder if any of the following 3 criteria were met: 1. WOMAC Pain (in 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 2. WOMAC Function (in normalized 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 3. At least 2 of the following 3 are met: WOMAC Pain improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; WOMAC Function improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; PGA improvement ≥ 20% and absolute change (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline. Response rate 95% confidence interval based on normal approximation.</description>
          <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, LOCF.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.4" lower_limit="52.1" upper_limit="72.7"/>
                    <measurement group_id="O2" value="64.8" lower_limit="54.8" upper_limit="74.8"/>
                    <measurement group_id="O3" value="66.7" lower_limit="56.6" upper_limit="76.7"/>
                    <measurement group_id="O4" value="72.7" lower_limit="63.4" upper_limit="82.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.744</p_value>
            <p_value_desc>P-value for test of difference between each ABT-981 dose group and Placebo was from a Cochran-Mantel-Haenszel test using age group and K-L grade as stratification factors.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Response Rate Difference</param_type>
            <param_value>2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.9</ci_lower_limit>
            <ci_upper_limit>16.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.581</p_value>
            <p_value_desc>P-value for test of difference between each ABT-981 dose group and Placebo was from a Cochran-Mantel-Haenszel test using age group and K-L grade as stratification factors.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Response Rate Difference</param_type>
            <param_value>4.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.1</ci_lower_limit>
            <ci_upper_limit>18.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.146</p_value>
            <p_value_desc>P-value for test of difference between each ABT-981 dose group and Placebo was from a Cochran-Mantel-Haenszel test using age group and K-L grade as stratification factors.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Response Rate Difference</param_type>
            <param_value>10.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>24.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 52</title>
        <description>Percentage of participants classified as OMERACT-OARSI responders at Week 52. A subject was considered an OMERACT-OARSI responder if any of the following 3 criteria were met: 1. WOMAC Pain (in 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 2. WOMAC Function (in normalized 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 3. At least 2 of the following 3 are met: WOMAC Pain improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; WOMAC Function improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; PGA improvement ≥ 20% and absolute change (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline. Response rate 95% confidence interval based on normal approximation.</description>
        <time_frame>Week 52</time_frame>
        <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo SC E2W</description>
          </group>
          <group group_id="O2">
            <title>ABT-981 25 mg</title>
            <description>25 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O3">
            <title>ABT-981 100 mg</title>
            <description>100 mg ABT-981 SC E2W</description>
          </group>
          <group group_id="O4">
            <title>ABT-981 200 mg</title>
            <description>200 mg ABT-981 SC E2W</description>
          </group>
        </group_list>
        <measure>
          <title>Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 52</title>
          <description>Percentage of participants classified as OMERACT-OARSI responders at Week 52. A subject was considered an OMERACT-OARSI responder if any of the following 3 criteria were met: 1. WOMAC Pain (in 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 2. WOMAC Function (in normalized 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 3. At least 2 of the following 3 are met: WOMAC Pain improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; WOMAC Function improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; PGA improvement ≥ 20% and absolute change (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline. Response rate 95% confidence interval based on normal approximation.</description>
          <population>Modified Intent to Treat population: all participants who received at least 1 dose of study drug, LOCF.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.6" lower_limit="60.9" upper_limit="80.3"/>
                    <measurement group_id="O2" value="69.3" lower_limit="59.7" upper_limit="79.0"/>
                    <measurement group_id="O3" value="71.4" lower_limit="61.8" upper_limit="81.1"/>
                    <measurement group_id="O4" value="72.7" lower_limit="63.4" upper_limit="82.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.824</p_value>
            <p_value_desc>P-value for test of difference between each ABT-981 dose group and Placebo was from a Cochran-Mantel-Haenszel test using age group and K-L grade as stratification factors.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Response Rate Difference</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.9</ci_lower_limit>
            <ci_upper_limit>12.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.964</p_value>
            <p_value_desc>P-value for test of difference between each ABT-981 dose group and Placebo was from a Cochran-Mantel-Haenszel test using age group and K-L grade as stratification factors.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Response Rate Difference</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.8</ci_lower_limit>
            <ci_upper_limit>14.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.763</p_value>
            <p_value_desc>P-value for test of difference between each ABT-981 dose group and Placebo was from a Cochran-Mantel-Haenszel test using age group and K-L grade as stratification factors.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Response Rate Difference</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.3</ci_lower_limit>
            <ci_upper_limit>15.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to Week 52 (or last dose of study drug) plus 70 days</time_frame>
      <desc>Safety population: all participants who took at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matching placebo SC E2W</description>
        </group>
        <group group_id="E2">
          <title>ABT-981 25 mg</title>
          <description>25 mg ABT-981 SC E2W</description>
        </group>
        <group group_id="E3">
          <title>ABT-981 100 mg</title>
          <description>100 mg ABT-981 SC E2W</description>
        </group>
        <group group_id="E4">
          <title>ABT-981 200 mg</title>
          <description>200 mg ABT-981 SC E2W</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>ADRENAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>LIVER DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>CERVICAL VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>JOINT INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>PROCEDURAL INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>SKULL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>TIBIA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>COLON ADENOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>INVASIVE DUCTAL BREAST CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>LUNG CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>AQUEDUCTAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>BRAIN OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>HYDROCEPHALUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>PARKINSON'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>SEIZURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ALVEOLITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="75" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>INJECTION SITE RASH</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>INJECTION SITE REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>LIGAMENT SPRAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie</organization>
      <phone>AbbVie</phone>
      <email>abbvieclinicaltrials@abbvie.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

